S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   906.12 (+0.40%)
NIO   4.62 (-1.07%)
AMD   181.89 (+1.28%)
BABA   72.41 (+1.15%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.95 (-2.87%)
DIS   122.35 (+1.13%)
AMC   3.78 (-12.90%)
PFE   27.87 (+0.32%)
PYPL   67.14 (+0.86%)
XOM   115.64 (+0.58%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   906.12 (+0.40%)
NIO   4.62 (-1.07%)
AMD   181.89 (+1.28%)
BABA   72.41 (+1.15%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.95 (-2.87%)
DIS   122.35 (+1.13%)
AMC   3.78 (-12.90%)
PFE   27.87 (+0.32%)
PYPL   67.14 (+0.86%)
XOM   115.64 (+0.58%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   906.12 (+0.40%)
NIO   4.62 (-1.07%)
AMD   181.89 (+1.28%)
BABA   72.41 (+1.15%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.95 (-2.87%)
DIS   122.35 (+1.13%)
AMC   3.78 (-12.90%)
PFE   27.87 (+0.32%)
PYPL   67.14 (+0.86%)
XOM   115.64 (+0.58%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   906.12 (+0.40%)
NIO   4.62 (-1.07%)
AMD   181.89 (+1.28%)
BABA   72.41 (+1.15%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.95 (-2.87%)
DIS   122.35 (+1.13%)
AMC   3.78 (-12.90%)
PFE   27.87 (+0.32%)
PYPL   67.14 (+0.86%)
XOM   115.64 (+0.58%)

Rallybio (RLYB) Stock Price, News & Analysis

$1.67
+0.08 (+5.03%)
(As of 11:10 AM ET)
Today's Range
$1.59
$1.67
50-Day Range
$1.25
$2.36
52-Week Range
$1.23
$9.14
Volume
37,739 shs
Average Volume
224,324 shs
Market Capitalization
$63.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.60

Rallybio MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
654.5% Upside
$12.60 Price Target
Short Interest
Bearish
7.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.89mentions of Rallybio in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.60) to ($1.49) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.48 out of 5 stars

Medical Sector

764th out of 939 stocks

Pharmaceutical Preparations Industry

354th out of 433 stocks

RLYB stock logo

About Rallybio Stock (NASDAQ:RLYB)

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

RLYB Stock Price History

RLYB Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Rallybio: Q4 Earnings Insights
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Rallybio Corp RLYB
See More Headlines
Receive RLYB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rallybio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2023
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RLYB
Fax
N/A
Employees
43
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.60
High Stock Price Target
$18.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+687.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-74,560,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.81 per share

Miscellaneous

Free Float
35,619,000
Market Cap
$60.50 million
Optionable
Not Optionable
Beta
-1.60
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Martin W. MacKay Ph.D. (Age 68)
    Co-Founder & Executive Chairman
    Comp: $707.07k
  • Dr. Stephen Uden M.B (Age 66)
    M.D., Co-Founder, President, CEO & Director
    Comp: $707.07k
  • Mr. Jonathan I. Lieber M.B.A. (Age 54)
    CFO & Treasurer
  • Ms. Ami Bavishi
    Head of Investor Relations & Corporate Communications
  • Dr. Steven W. Ryder F.A.C.P (Age 72)
    M.D., Chief Medical Officer

RLYB Stock Analysis - Frequently Asked Questions

Should I buy or sell Rallybio stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rallybio in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RLYB shares.
View RLYB analyst ratings
or view top-rated stocks.

What is Rallybio's stock price target for 2024?

6 brokers have issued 12 month price objectives for Rallybio's shares. Their RLYB share price targets range from $8.00 to $18.00. On average, they expect the company's share price to reach $12.60 in the next year. This suggests a possible upside of 654.5% from the stock's current price.
View analysts price targets for RLYB
or view top-rated stocks among Wall Street analysts.

How have RLYB shares performed in 2024?

Rallybio's stock was trading at $2.39 at the beginning of 2024. Since then, RLYB stock has decreased by 30.1% and is now trading at $1.67.
View the best growth stocks for 2024 here
.

When is Rallybio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RLYB earnings forecast
.

How were Rallybio's earnings last quarter?

Rallybio Co. (NASDAQ:RLYB) issued its quarterly earnings results on Monday, March, 6th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.60) by $0.14.

When did Rallybio IPO?

Rallybio (RLYB) raised $80 million in an initial public offering on Thursday, July 29th 2021. The company issued 5,750,000 shares at $13.00-$15.00 per share.

Who are Rallybio's major shareholders?

Rallybio's stock is owned by many different retail and institutional investors. Top institutional investors include Novo Holdings A S (4.68%), abrdn plc (4.57%), Vanguard Group Inc. (2.82%), Vanguard Group Inc. (2.82%), Blue Owl Capital Holdings LP (0.93%) and Citadel Advisors LLC (0.84%). Insiders that own company stock include Jeffrey M Fryer, Jonathan I Lieber, Kush Parmar, Martin Mackay, Opportunities I LP 5Am and Stephen Uden.
View institutional ownership trends
.

How do I buy shares of Rallybio?

Shares of RLYB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RLYB) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners